Form 4: Berkshire Hathaway Sells Additional Shares of DaVita Inc. (DVA)

Berkshire Hathaway, along with Warren Buffett, reports the sale of additional DaVita Inc. shares between February 14 and February 19, 2025, reducing their indirect holdings.

Summary

• Berkshire Hathaway Inc. and Warren E. Buffett reported the sale of DaVita Inc. (DVA) common stock.
• The sales occurred on multiple dates: February 14, 2025, February 18, 2025, and February 19, 2025.
• The sales prices ranged from $150.1200 to $159.1900 per share on February 14, 2025.
• The sales prices ranged from $153.1100 to $158.01 per share on February 18, 2025.
• The sales prices ranged from $153.0000 to $155.5600 per share on February 19, 2025.
• A total of 693,181 shares were sold across all transactions.
• Following these transactions, Berkshire Hathaway's indirect beneficial ownership in DaVita decreased to 35,142,479 shares.
• The reported sales were executed under Rule 10b5-1(c).

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to Berkshire Hathaway reducing its stake in DaVita, which could indicate a lack of confidence in the company's future prospects. However, the sales are being conducted under a pre-arranged trading plan, which mitigates some of the negative implications.

Negatives

• Berkshire Hathaway is reducing its stake in DaVita, which could be interpreted negatively by the market.

Risks

• Continued sales of DaVita shares by Berkshire Hathaway could put downward pressure on the stock price.
• The reasons behind Berkshire Hathaway's decision to sell shares are not disclosed, creating uncertainty.

Future Outlook

The document does not provide any specific forward-looking statements regarding DaVita's future performance or Berkshire Hathaway's future transactions.

Industry Context

The healthcare services industry, particularly dialysis providers like DaVita, is subject to regulatory scrutiny and reimbursement pressures. Major shareholders like Berkshire Hathaway adjusting their positions can reflect their assessment of these industry dynamics and company-specific factors.

Comparison to Industry Standards

• It's important to compare DaVita's performance and valuation metrics against its primary competitor, Fresenius Medical Care (FMS), to understand its relative position in the dialysis services market.
• Analyzing the trading activity of other major healthcare investors can provide context for Berkshire Hathaway's actions.
• Comparing DaVita's financial ratios (e.g., P/E, debt-to-equity) to industry averages can offer insights into its valuation.

Stakeholder Impact

• Shareholders may react negatively to the news of Berkshire Hathaway selling shares.
• The sales could put downward pressure on DaVita's stock price.

Key Dates

Keywords

DaVita, Berkshire Hathaway, Warren Buffett, Share Sale, DVA, Form 4, Beneficial Ownership, Stock Transaction